Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramses Forsyth

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal for Immunotherapy of Cancer|January 11, 2024
Intratumoral administration of the immunologic adjuvant AS01<sub>B</sub> in combination with autologous CD1c (BDCA-1)<sup>+</sup>/CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanomaJens Tijtgat, Xenia Geeraerts, Anais Boisson, et al.
Cancer Genetics and Cytogenetics|June 5, 2003
Evidence for involvement of a tumor suppressor gene on 1p in malignant peripheral nerve sheath tumorsNadine Van Roy, Mireille Van Gele, Jo Vandesompele, et al.
Histopathology|November 1, 2011
Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bonePeter Balla, Linda Moskovszky, Zoltan Sapi, et al.
Journal of Healthcare Informatics Research|February 9, 2026
Unlocking Health Data for Research: Legal, Technical, and Organisational Lessons from a Belgian Interdisciplinary Case StudyAudrey Van Scharen, Karen Cruyt, Jeroen Colon, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)<sup>+</sup>/CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells in solid tumorsManon Vounckx, Jens Tijtgat, Latoya Stevens, et al.
The International Journal of Cardiovascular Imaging|December 5, 2022
Prognostic value of left ventricular global constructive work in patients with cardiac amyloidosisJolien Geers, Maria-Luiza Luchian, Andreea Motoc, et al.
Journal for Immunotherapy of Cancer|June 25, 2021
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trialJohnny Duerinck, Julia Katharina Schwarze, Gil Awada, et al.
Nature Genetics|March 22, 2006
Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndromePaul J Coucke, Andy Willaert, Marja W Wessels, et al.
Cancer Research|September 17, 2025
Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD-1 ImmunotherapySana M Arnouk, Daliya Kancheva, Helena Van Damme, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal for Immunotherapy of Cancer|January 11, 2024
Intratumoral administration of the immunologic adjuvant AS01<sub>B</sub> in combination with autologous CD1c (BDCA-1)<sup>+</sup>/CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanomaJens Tijtgat, Xenia Geeraerts, Anais Boisson, et al.
Cancer Genetics and Cytogenetics|June 5, 2003
Evidence for involvement of a tumor suppressor gene on 1p in malignant peripheral nerve sheath tumorsNadine Van Roy, Mireille Van Gele, Jo Vandesompele, et al.
Histopathology|November 1, 2011
Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bonePeter Balla, Linda Moskovszky, Zoltan Sapi, et al.
Journal of Healthcare Informatics Research|February 9, 2026
Unlocking Health Data for Research: Legal, Technical, and Organisational Lessons from a Belgian Interdisciplinary Case StudyAudrey Van Scharen, Karen Cruyt, Jeroen Colon, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)<sup>+</sup>/CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells in solid tumorsManon Vounckx, Jens Tijtgat, Latoya Stevens, et al.
The International Journal of Cardiovascular Imaging|December 5, 2022
Prognostic value of left ventricular global constructive work in patients with cardiac amyloidosisJolien Geers, Maria-Luiza Luchian, Andreea Motoc, et al.
Journal for Immunotherapy of Cancer|June 25, 2021
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trialJohnny Duerinck, Julia Katharina Schwarze, Gil Awada, et al.
Nature Genetics|March 22, 2006
Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndromePaul J Coucke, Andy Willaert, Marja W Wessels, et al.
Cancer Research|September 17, 2025
Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD-1 ImmunotherapySana M Arnouk, Daliya Kancheva, Helena Van Damme, et al.
Pageof 5